Reuters logo
FDA rejects Dynavax's adult hep B vaccine on safety concerns
February 25, 2013 / 11:11 AM / 5 years ago

FDA rejects Dynavax's adult hep B vaccine on safety concerns

Feb 25 (Reuters) - U.S. health regulators denied approval to Dynavax Technologies Inc’s adult hepatitis B vaccine in its current form and asked for more data to evaluate the vaccine’s safety.

The U.S. Food and Drug Administration indicated it was willing to have discussions for a more restricted use of the vaccine Heplisav, Dynavax said in a statement.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below